E.g., 01/28/2021
E.g., 01/28/2021

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.

17 November, 2020

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.

First-Half 2020 Results

02 September, 2020

bioMerieux CE Mark of VIDAS Serology test for SARS-COV-2

26 May, 2020

bioMérieux announces the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease. Read more here

COVID-19 Business Continuity

23 March, 2020

Information on business continuity for all our customers at the current time.

Introducing a total sepsis solution at NHS Greater Glasgow and Clyde

26 September, 2019

A campaign to raise awareness of sepsis in Scotland, combined with the introduction of the latest technology in microbiology, has had a positive impact on the speed of clinical intervention and potential outcomes in the fight against this serious condition, as Janet Young explains.  Read the full article here. (Licenced from Pathology in Practice Volume 20, Issue 5, October 2019)  

Pioneering Diagnostics